According to GlobalData, out of the clinical trials with a 2024 start date, 41.4% of trials were ongoing, recruiting; 32.2% ...

The global clinical trials market is anticipated to grow at a CAGR of 6-7% from 2024 to 2029. This growth is driven by the ...

A partnership between a senior living organization and a research company is bridging the gap between clinical research and ...

Oculis Holding has concluded subject enrolment for the Phase III DIAMOND-1 and DIAMOND-2 clinical trials of OCS-01 eye drops ...

With the continuing cuts to US Food and Drug Administration (FDA) staffing, the pharmaceutical and biotechnology industries are ...

Veeva Systems VEEV recently introduced SiteVault, a Clinical Trial Management System (CTMS) designed for research sites. It ...

In addition, in the second half of 2025, Verve remains on track to report the final data for the dose escalation portion of the Heart-2 clinical trial, deliver the opt-in package for the PCSK9 program ...

The National Medical Products Administration, China's top drug regulator, approved the vaccine for clinical trials in ...

The Labour manifesto pledged to “maximise our potential to lead the world in clinical trials”. With our regulatory advantage ...

The findings reinforce the potential of BRIUMVI in improving patient outcomes for those seeking an alternative to their previous anti-CD20 therapy. Furthermore, the article in CNS DRUGS offers an ...

DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME) Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an ...